Emerging drugs for chronic urticaria (Q36458408)

14 August 2017

1 reference

title

Emerging drugs for chronic urticaria (English)

1 reference

14 August 2017

1 reference

Riccardo Asero

1

1 reference

14 August 2017

Alberto Tedeschi

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

Expert Opinion on Emerging Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

265-274

1 reference

Urticaria and angio-oedema. A review of 554 patients

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Urticaria. An updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria. Evaluation of the role of physical, immunologic, and other contributory factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic idiopathic urticaria: a family study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Clinical practice. Chronic urticaria and angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression--inhibitory effects ofanti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria: novel clinical and serological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

The paradigm of type 1 and type 2 antigen-presenting cells. Implications for atopic allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Loratadine in the treatment of urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Desloratadine in the treatment of chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria: assessment of current treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Cimetidine in chronic idiopathic urticaria: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Leukotriene modifiers in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Zafirlukast has no beneficial effects in the treatment of chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Leukotriene receptor antagonists in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Methotrexate-responsive chronic idiopathic urticaria: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Plasmapheresis for severe, unremitting, chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

The hypocomplementemic urticarial-vasculitis syndrome: Therapeutic response to hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Urticaria treated with dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria and angioedema associated with thyroid autoimmunity: review and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

The treatment of glucocorticosteroid-dependent chronic urticaria with stanozolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria with angio-oedema controlled by warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Warfarin treatment of chronic idiopathic urticaria and angio-oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Contact allergic dermatitis and life-threatening anaphylaxis to chlorhexidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Are confusion and controversy about food hypersensitivity really necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Autoantibodies against the High-Affinity IgE Receptor as a Cause of Histamine Release in Chronic Urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Complement dependence of histamine release in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Not all chronic urticaria is “idiopathic”

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic idiopathic urticaria: Possible contribution of histamine-releasing factor to pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Efficacy of doxepin in the treatment of chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

A controlled trial of therapy in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Skin responses to intradermal histamine and leukotrienes C4, D4, and E4 in patients with chronic idiopathic urticaria and in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Antileukotrienes in chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Successful treatment of chronic urticaria with leukotriene antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Successful treatment of chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Successful treatment of delayed pressure urticaria with montelukast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Oral cyclosporine for severe chronic idiopathic urticaria and angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Intravenous immunoglobulin in autoimmune chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Are IVIG for chronic unremitting urticaria effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Resolution of chronic urticaria in patients with thyroid autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Chronic urticaria responding to subcutaneous heparin sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Warfarin sodium therapy for chronic urticaria and angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Warfarin in the treatment of chronic urticaria/angio-edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14728214.11.2.265

10.1517/14728214.11.2.265

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference